NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials

NeuroDerm’s clinical development plan remains on track with its previously announced timelines both in the US and EU. ”> Read More

NeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting

An Encore Presentation Will be Given at the Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance in the Field of Neuroscience; A Platform Presentation on the Effects of Continuously Delivered Carbidopa on Levodopa Bioavailability Will Also be Presented at the Movement Disorders: Parkinson’s Disease Clinical Trials and Therapeutics Session. > Read More

NeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update

Company to Host Conference Call and Webcast Today at 8:30 a.m. ET. > Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.